XML 41 R28.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-Based Compensation (Tables)
 3 Months Ended
Mar. 31, 2021
Share-based Payment Arrangement [Abstract]  
Schedule of Stock-Based Compensation Expense
Stock-based compensation expense for options granted, restricted stock awards (“RSAs”), RSAs with non-market performance and service conditions (“PSAs”), restricted stock units (“RSUs”) and stock appreciation rights (“SARs”) is reflected in the condensed consolidated statements of operations and comprehensive loss as follows:
 THREE MONTHS ENDED 
MARCH 31,
(in thousands)20212020
Cost of goods sold$507 $497 
Selling, general and administrative6,255 6,908 
Pre-approval commercial manufacturing— 294 
Research and development1,987 2,830 
Total$8,749 $10,529 
Schedule of Stock Options Activity
The following table summarizes the stock option activity under the Plans:
NUMBER OF
SHARES		WEIGHTED AVERAGE
EXERCISE PRICE		WEIGHTED
AVERAGE
REMAINING
CONTRACTUAL
LIFE (YEARS)		AGGREGATE
INTRINSIC
VALUE
(000’s)
Options outstanding at December 31, 2020
8,588,614 $27.36 
Granted421,280 17.50 
Exercised(63,370)0.76 
Canceled(226,156)38.78 
Options outstanding at March 31, 2021
8,720,368 $26.78 5.9$23,551 
Options exercisable at March 31, 2021
6,464,439 $26.66 4.9$21,828 
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity
The following table summarizes the RSA, including PSA, activity under the Plans:
NUMBER OF
SHARES		WEIGHTED AVERAGE
FAIR VALUE PER SHARE
Non-vested RSAs at December 31, 2020
809,527 $29.03 
Granted94,132 17.61 
Vested(160,259)44.62 
Canceled(29,395)23.86 
Non-vested RSAs at March 31, 2021
714,005 $24.23 
The following table summarizes the RSU activity under the Plans:
NUMBER OF
SHARES		WEIGHTED AVERAGE
FAIR VALUE PER SHARE
Non-vested RSUs at December 31, 2020
107,182 $14.43 
Granted1,407 19.18 
Vested(11,035)19.25 
Canceled(2,316)14.34 
Non-vested RSUs at March 31, 2021
95,238 $13.95 
Schedule of Stock Appreciation Rights
The following table summarizes the SAR activity under the Plans:
NUMBER OF
SHARES		WEIGHTED AVERAGE
EXERCISE PRICE		WEIGHTED
AVERAGE
REMAINING
CONTRACTUAL
LIFE (YEARS)		AGGREGATE
INTRINSIC
VALUE
(000’s)
SARs outstanding at December 31, 2020
212,044 $32.28 
Granted5,000 18.68 
Canceled(13,801)28.43 
SARs outstanding at March 31, 2021
203,243 $32.20 3.3$280 
SARs exercisable at March 31, 2021
66,546 $45.16 2.5$3